Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2021 | Nov. 12, 2021 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0000811212 | |
Entity Registrant Name | ThermoGenesis Holdings, Inc. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2021 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 333-82900 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 94-3018487 | |
Entity Address, Address Line One | 2711 Citrus Road | |
Entity Address, City or Town | Rancho Cordova | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 95742 | |
City Area Code | 916 | |
Local Phone Number | 858-5100 | |
Title of 12(b) Security | Common Stock, $.001 par value | |
Trading Symbol | THMO | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 11,911,784 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 7,634,000 | $ 7,161,000 |
Accounts receivable, net of allowance for doubtful accounts of $212,000 at September 30, 2021 ($214,000 at December 31, 2020) | 2,571,000 | 1,382,000 |
Inventories | 5,538,000 | 5,877,000 |
Prepaid expenses and other current assets | 1,138,000 | 878,000 |
Total current assets | 16,881,000 | 15,298,000 |
Inventories, non-current | 1,784,000 | 1,221,000 |
Equipment and leasehold improvements, net | 1,339,000 | 1,424,000 |
Right-of-use operating lease assets, net | 614,000 | 730,000 |
Goodwill | 781,000 | 781,000 |
Other intangible assets, net | 1,326,000 | 1,358,000 |
Other assets | 48,000 | 48,000 |
Total assets | 22,773,000 | 20,860,000 |
Current liabilities: | ||
Accounts payable | 1,502,000 | 1,366,000 |
Accrued payroll and related expenses | 461,000 | 349,000 |
Deferred revenue – short-term | 943,000 | 608,000 |
Convertible promissory note – related party, net | 8,417,000 | |
Interest payable – related party | 1,668,000 | 2,082,000 |
Note payable – short-term | 447,000 | |
Convertible promissory note, net | 733,000 | |
Other current liabilities | 1,011,000 | 1,291,000 |
Total current liabilities | 14,735,000 | 6,143,000 |
Convertible promissory note – related party, net | 5,935,000 | |
Convertible promissory note, net | 493,000 | |
Note payable | 199,000 | |
Operating lease obligations – long-term | 455,000 | 604,000 |
Deferred revenue – long-term | 1,395,000 | 1,596,000 |
Other noncurrent liabilities | 20,000 | 20,000 |
Total liabilities | 16,605,000 | 14,990,000 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding | 0 | 0 |
Common stock, $0.001 par value; 350,000,000 shares authorized; 11,911,784 issued and outstanding (8,934,952 at December 31, 2020) | 12,000 | 9,000 |
Additional paid in capital | 268,336,000 | 259,058,000 |
Accumulated deficit | (262,009,000) | (253,283,000) |
Accumulated other comprehensive loss | 28,000 | 16,000 |
Total ThermoGenesis Holdings, Inc. stockholders’ equity | 6,367,000 | 5,800,000 |
Noncontrolling interests | (199,000) | 70,000 |
Total equity | 6,168,000 | 5,870,000 |
Total liabilities and equity | $ 22,773,000 | $ 20,860,000 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Accounts receivable, allowance for doubtful accounts | $ 212,000 | $ 214,000 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 2,000,000 | 2,000,000 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 350,000,000 | 350,000,000 |
Common stock, shares issued (in shares) | 11,911,784 | 8,934,952 |
Common stock, shares outstanding (in shares) | 11,911,784 | 8,934,952 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Net revenues | $ 3,158,000 | $ 2,355,000 | $ 6,876,000 | $ 7,797,000 |
Cost of revenues | 2,043,000 | 844,000 | 4,067,000 | 7,426,000 |
Gross profit (loss) | 1,115,000 | 1,511,000 | 2,809,000 | 371,000 |
Expenses: | ||||
Selling, general and administrative | 1,677,000 | 1,844,000 | 7,171,000 | 5,913,000 |
Research and development | 543,000 | 750,000 | 1,544,000 | 1,937,000 |
Total operating expenses | 2,220,000 | 2,594,000 | 8,715,000 | 7,850,000 |
Loss from operations | (1,105,000) | (1,083,000) | (5,906,000) | (7,479,000) |
Other expenses: | ||||
Interest expense | (1,530,000) | (1,531,000) | (4,573,000) | (6,377,000) |
Gain/(loss) on extinguishment of debt | 652,000 | |||
Other income/(expense) | 843,000 | 5,000 | 833,000 | (6,000) |
Total other expense | (687,000) | (1,526,000) | (3,088,000) | (6,383,000) |
Net loss | (1,792,000) | (2,609,000) | (8,994,000) | (13,862,000) |
Loss attributable to noncontrolling interests | (18,000) | (146,000) | (269,000) | (360,000) |
Net loss attributable to common stockholders | (1,774,000) | (2,463,000) | (8,725,000) | (13,502,000) |
Net loss | (1,792,000) | (2,609,000) | (8,994,000) | (13,862,000) |
Other comprehensive loss: | ||||
Foreign currency translation adjustments gain (loss) | (1,000) | (19,000) | 12,000 | 20,000 |
Comprehensive loss | (1,793,000) | (2,628,000) | (8,982,000) | (13,842,000) |
Comprehensive loss attributable to noncontrolling interests | (18,000) | (146,000) | (269,000) | (360,000) |
Comprehensive loss attributable to common stockholders | $ (1,775,000) | $ (2,482,000) | $ (8,713,000) | $ (13,482,000) |
Per share data: | ||||
Basic and diluted net loss per common share (in dollars per share) | $ (0.15) | $ (0.37) | $ (0.74) | $ (2.36) |
Weighted average common shares outstanding – basic and diluted (in shares) | 11,911,784 | 6,711,664 | 11,757,211 | 5,728,105 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Equity (Unaudited) - USD ($) | At The Market Offering Agreement [Member]Common Stock [Member] | At The Market Offering Agreement [Member]Additional Paid-in Capital [Member] | At The Market Offering Agreement [Member] | Boyalife Asset Holding II [Member]Common Stock [Member] | Boyalife Asset Holding II [Member]Additional Paid-in Capital [Member] | Boyalife Asset Holding II [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Noncontrolling Interest [Member] | Total | |
Balance (in shares) at Dec. 31, 2019 | 2,843,601 | ||||||||||||
Balance at Dec. 31, 2019 | $ 3,000 | $ 237,313,000 | $ (236,932,000) | $ 2,000 | [1] | $ 530,000 | $ 916,000 | ||||||
Stock-based compensation expense | 67,000 | 67,000 | |||||||||||
Issuance of common stock (in shares) | 1,050,748 | ||||||||||||
Issuance of common stock | $ 1,000 | 3,220,000 | 3,221,000 | ||||||||||
Foreign currency translation gain (loss) | 38,000 | [1] | 38,000 | ||||||||||
Net loss | (4,602,000) | (141,000) | (4,743,000) | ||||||||||
Exercise of pre-funded warrants (in shares) | 100,000 | ||||||||||||
Exercise of pre-funded warrants | 10,000 | 10,000 | |||||||||||
Exercise of warrants (in shares) | 7,866 | ||||||||||||
Exercise of warrants | 47,000 | 47,000 | |||||||||||
Discount due to beneficial conversion features | 1,869,000 | 1,869,000 | |||||||||||
Conversion of note payable to common stock (in shares) | 1,666,670 | 100,000 | |||||||||||
Conversion of related party note payable to common stock | $ 2,000 | $ 2,998,000 | $ 3,000,000 | 180,000 | 180,000 | ||||||||
Balance (in shares) at Mar. 31, 2020 | 5,768,885 | ||||||||||||
Balance at Mar. 31, 2020 | $ 6,000 | 245,704,000 | (241,534,000) | 40,000 | [1] | 389,000 | 4,605,000 | ||||||
Balance (in shares) at Dec. 31, 2019 | 2,843,601 | ||||||||||||
Balance at Dec. 31, 2019 | $ 3,000 | 237,313,000 | (236,932,000) | 2,000 | [1] | 530,000 | 916,000 | ||||||
Foreign currency translation gain (loss) | 20,000 | ||||||||||||
Balance (in shares) at Sep. 30, 2020 | 6,832,040 | ||||||||||||
Balance at Sep. 30, 2020 | $ 7,000 | 253,537,000 | (250,434,000) | 22,000 | 170,000 | 3,302,000 | |||||||
Balance (in shares) at Mar. 31, 2020 | 5,768,885 | ||||||||||||
Balance at Mar. 31, 2020 | $ 6,000 | 245,704,000 | (241,534,000) | 40,000 | [1] | 389,000 | 4,605,000 | ||||||
Stock-based compensation expense | 314,000 | 314,000 | |||||||||||
Issuance of common stock (in shares) | 344,419 | ||||||||||||
Issuance of common stock | 1,993,000 | 1,993,000 | |||||||||||
Foreign currency translation gain (loss) | 1,000 | 1,000 | |||||||||||
Net loss | (6,437,000) | (73,000) | (6,510,000) | ||||||||||
Exercise of pre-funded warrants (in shares) | 224,445 | ||||||||||||
Exercise of pre-funded warrants | 22,000 | 22,000 | |||||||||||
Exercise of warrants (in shares) | 267,271 | ||||||||||||
Exercise of warrants | 1,604,000 | 1,604,000 | |||||||||||
Discount due to beneficial conversion features | 3,112,000 | 3,112,000 | |||||||||||
Conversion of note payable to common stock (in shares) | 104,445 | ||||||||||||
Conversion of related party note payable to common stock | $ 1,000 | 188,000 | 189,000 | ||||||||||
Balance (in shares) at Jun. 30, 2020 | 6,709,465 | ||||||||||||
Balance at Jun. 30, 2020 | $ 7,000 | 252,937,000 | (247,971,000) | 41,000 | [1] | 316,000 | 5,330,000 | ||||||
Stock-based compensation expense | 234,000 | 234,000 | |||||||||||
Issuance of common stock (in shares) | 122,575 | ||||||||||||
Issuance of common stock | 366,000 | 366,000 | |||||||||||
Foreign currency translation gain (loss) | (19,000) | (19,000) | |||||||||||
Net loss | (2,463,000) | (146,000) | (2,609,000) | ||||||||||
Balance (in shares) at Sep. 30, 2020 | 6,832,040 | ||||||||||||
Balance at Sep. 30, 2020 | $ 7,000 | 253,537,000 | (250,434,000) | 22,000 | 170,000 | 3,302,000 | |||||||
Balance (in shares) at Dec. 31, 2020 | 8,934,952 | ||||||||||||
Balance at Dec. 31, 2020 | $ 9,000 | 259,058,000 | (253,283,000) | 16,000 | [1] | 70,000 | 5,870,000 | ||||||
Stock-based compensation expense | 258,000 | 258,000 | |||||||||||
Issuance of common stock (in shares) | 2,976,832 | ||||||||||||
Issuance of common stock | $ 3,000 | $ 6,829,000 | $ 6,832,000 | ||||||||||
Foreign currency translation gain (loss) | 1,000 | [1] | 1,000 | ||||||||||
Net loss | (2,413,000) | (118,000) | (2,531,000) | ||||||||||
Balance (in shares) at Mar. 31, 2021 | 11,911,784 | ||||||||||||
Balance at Mar. 31, 2021 | $ 12,000 | 266,145,000 | (255,696,000) | 17,000 | [1] | (48,000) | 10,430,000 | ||||||
Balance (in shares) at Dec. 31, 2020 | 8,934,952 | ||||||||||||
Balance at Dec. 31, 2020 | $ 9,000 | 259,058,000 | (253,283,000) | 16,000 | [1] | 70,000 | 5,870,000 | ||||||
Issuance of common stock (in shares) | 2,976,832 | ||||||||||||
Foreign currency translation gain (loss) | 12,000 | ||||||||||||
Balance (in shares) at Sep. 30, 2021 | 11,911,784 | ||||||||||||
Balance at Sep. 30, 2021 | $ 12,000 | 268,336,000 | (262,009,000) | 28,000 | (199,000) | 6,168,000 | |||||||
Balance (in shares) at Mar. 31, 2021 | 11,911,784 | ||||||||||||
Balance at Mar. 31, 2021 | $ 12,000 | 266,145,000 | (255,696,000) | 17,000 | [1] | (48,000) | 10,430,000 | ||||||
Stock-based compensation expense | 2,099,000 | 2,099,000 | |||||||||||
Foreign currency translation gain (loss) | 12,000 | 12,000 | |||||||||||
Net loss | (4,539,000) | (133,000) | (4,672,000) | ||||||||||
Balance (in shares) at Jun. 30, 2021 | 11,911,784 | ||||||||||||
Balance at Jun. 30, 2021 | $ 12,000 | 268,244,000 | (260,235,000) | 29,000 | [1] | (181,000) | 7,869,000 | ||||||
Stock-based compensation expense | 92,000 | 92,000 | |||||||||||
Foreign currency translation gain (loss) | (1,000) | (1,000) | |||||||||||
Net loss | (1,774,000) | (18,000) | (1,792,000) | ||||||||||
Balance (in shares) at Sep. 30, 2021 | 11,911,784 | ||||||||||||
Balance at Sep. 30, 2021 | $ 12,000 | $ 268,336,000 | $ (262,009,000) | $ 28,000 | $ (199,000) | $ 6,168,000 | |||||||
[1] | Accumulated other comprehensive loss. |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Cash flows from operating activities: | ||
Net loss | $ (8,994,000) | $ (13,862,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 477,000 | 569,000 |
Stock based compensation expense | 2,449,000 | 615,000 |
Amortization of debt discount/premium, net | 2,723,000 | 2,165,000 |
Amortization of accelerated debt discount due to conversion | 2,486,000 | |
Reserve for excess and slow-moving inventories | 336,000 | 4,036,000 |
Reserve for bad debt expense | (6,000) | |
Loss on disposal of equipment | 118,000 | |
Gain on extinguishment of debt | (652,000) | |
Net change in operating assets and liabilities: | ||
Accounts receivable | (1,190,000) | (414,000) |
Inventories | (742,000) | (6,086,000) |
Prepaid expenses and other assets | (260,000) | 6,000 |
Accounts payable | 145,000 | 223,000 |
Interest payable - related party | (413,000) | (350,000) |
Accrued payroll and related expenses | 111,000 | 225,000 |
Deferred revenue – short-term | 334,000 | 80,000 |
Other current liabilities | (271,000) | (1,326,000) |
Long-term deferred revenue and other noncurrent liabilities | (347,000) | (338,000) |
Net cash used in operating activities | (6,294,000) | (11,859,000) |
Cash flows from investing activities: | ||
Capital expenditures | (64,000) | (23,000) |
Net cash used in investing activities | (64,000) | (23,000) |
Cash flows from financing activities: | ||
Proceeds from convertible promissory note-related party | 4,287,000 | |
Payments on financing lease obligations | (32,000) | |
Proceeds from issuance of common stock, net of expenses | 6,832,000 | 5,580,000 |
Proceeds from exercise of options, warrants and pre-funded warrants | 1,683,000 | |
Proceeds from note payable | 646,000 | |
Net cash provided by financing activities | 6,832,000 | 12,164,000 |
Effects of foreign currency rate changes on cash and cash equivalents | (1,000) | (3,000) |
Net increase (decrease) in cash, cash equivalents and restricted cash | 473,000 | 279,000 |
Cash, cash equivalents and restricted cash at beginning of period | 7,161,000 | 4,157,000 |
Cash, cash equivalents and restricted cash at end of period | 7,634,000 | 4,436,000 |
Supplemental disclosures of cash flow information: | ||
Cash paid for interest | 2,262,000 | 2,094,000 |
Supplemental non-cash financing and investing information: | ||
Recording of beneficial conversion feature on debt | 4,981,000 | |
Transfer of inventory to fixed assets | $ 181,000 | |
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member] | ||
Supplemental non-cash financing and investing information: | ||
Related party promissory note converted to common stock | 3,000,000 | |
Conversion of January 2019 Amended Notes to Common Stock [Member] | ||
Supplemental non-cash financing and investing information: | ||
Related party promissory note converted to common stock | $ 369,000 |
Note 1 - Description of Busines
Note 1 - Description of Business and Basis of Presentation | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Description of Business ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”), develops, commercializes and markets a range of automated technologies for chimeric antigen receptor therapies (“CAR-T”) and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 The Company provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and CAR-TXpress™ platform for bio-manufacturing for immuno-oncology applications. The Company and its subsidiaries currently manufacture and market the following products: Clinical Bio-Banking Applications: ● AXP® 510 ● BioArchive® Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications, registered as a U.S. FDA 510 Point-of-Care Applications: ● PXP® 510 ● PXP-LAVARE System – an automated, fully closed system that is designed to wash, re-suspend and volume reduce cell suspensions. It allows for volume manipulation, supernatant or media exchange, and cell washing to occur without comprising cell viabilities and maximizing recoveries, registered as a U.S. FDA 510 ● PXP- 1000 510 Large Scale Cell Processing and Biomanufacturing: ● X X X X X ● CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing CAR-T cell therapies. The CAR-TXpress Platform is owned and developed through a subsidiary CAR-TXpress Bio, Inc. (“CARTXpress Bio”) in which the Company owns 80% of the equity interest. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10 8 X. Operating results for the three September 30, 2021 not may December 31, 2021. 10 December 31, 2020. Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings, Inc. and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. The 20% ownership interest of CARTXpress Bio that is not |
Note 2 - Going Concern
Note 2 - Going Concern | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | 2. GOING CONCERN At September 30, 2021, may may one The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The condensed consolidated financial statements do not may |
Note 3 - Summary of Significant
Note 3 - Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES There have been no 10 December 31, 2020. Recently Adopted Accounting Standards In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020. not nine September 30, 2021 not In January 2020, 2020 01, Investments Equity Securities (Topic 321 Equity Method and Joint Ventures (Topic 323 815 321, 323, 815 December 15, 2020, not Revenue Recognition Revenue is recognized based on the five 606. The following tables summarize the revenues by product line: Three Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,217,000 $ 72,000 $ 21,000 $ 2,310,000 BioArchive 221,000 297,000 -- 518,000 CAR-TXpress 160,000 31,000 71,000 262,000 Manual Disposables 55,000 -- -- 55,000 Other 9,000 -- 4,000 13,000 Total $ 2,662,000 $ 400,000 $ 96,000 $ 3,158,000 Nine Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 3,490,000 $ 159,000 $ 1,000 $ 3,670,000 BioArchive 652,000 1,165,000 -- 1,817,000 CAR-TXpress 702,000 89,000 214,000 1,005,000 Manual Disposables 300,000 -- -- 300,000 Other 46,000 -- 38,000 84,000 Total $ 5,190,000 $ 1,413,000 $ 273,000 $ 6,876,000 Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three nine September 30, 2021 nine September 30, 2021, Exclusivity Fee On August 30, 2019, five two two four X three nine September 30, 2021 2020, Distribution Agreement The Company signed a new agreement with its AXP distributor in China through 2023. 2021, two 2024. September 30, 2021, five per quarter September 30, 2021, Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2021 2022 2023 2024 2025 and beyond Total Service revenue $ 359,000 $ 962,000 $ 462,000 $ 189,000 $ 85,000 $ 2,057,000 Clinical revenue 3,000 13,000 13,000 13,000 160,000 202,000 Device revenue (1) 21,000 674,000 674,000 41,000 -- 1,410,000 Exclusivity fee 72,000 286,000 286,000 286,000 476,000 1,406,000 Total $ 455,000 $ 1,935,000 $ 1,435,000 $ 529,000 $ 721,000 $ 5,075,000 ( 1 Represents the minimum purchase requirements related to the Company AXP distributor in China Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not three nine September 30, 2021, one |
Note 4 - Net Loss Per Share
Note 4 - Net Loss Per Share | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 4. NET LOSS PER SHARE Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no September 30: 2021 2020 Common stock equivalents of convertible promissory notes and accrued interest 7,071,241 6,988,334 Vested Series A warrants -- 40,441 Unvested Series A warrants (1) -- 69,853 Warrants – other 653,248 1,006,190 Stock options 366,595 892,149 Total 8,091,084 8,996,967 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021. |
Note 5 - Related Party Transact
Note 5 - Related Party Transactions | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 5. RELATED PARTY TRANSACTIONS HealthBanks Biotech (USA) Inc. On November 26, 2019 Between November 26, 2019 September 30, 2020, In March 2021, none no March 31, 2021. As of September 30, 2021, September 30, 2021, $750,000; Convertible Promissory Note and Revolving Credit Agreement In March 2017, March 6, 2022 ( September 30, 2021 December 31, 2020, The Credit Agreement and the Convertible Promissory Note issued thereunder (as amended, the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five January 2021, December 31, 2020 The Credit Agreement and Note were amended in April 2018, 2018, The following summarizes the Note: Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At September 30, 2021 3/6/2022 22% $1.80 $10,000,000 $(1,583,000) $8,417,000 At December 31, 2020 3/6/2022 22% $1.80 $10,000,000 $(4,065,000) $5,935,000 The Company amortized $827,000 and $2,482,000 of debt discount to interest expense for the three nine September 30, 2021 three nine September 30 2020, three nine September 30, 2021 three nine September 30 2020, September 30, 2021 December 31, 2020 |
Note 6 - Convertible Promissory
Note 6 - Convertible Promissory Note | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 6. CONVERTIBLE PROMISSORY NOTE July 2019 On July 23, 2019, “July 2019 July 2019 July 2019 twenty-four July 2019 three July 31, 2022. The following summarizes the July 2019 Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At September 30, 2021 7/31/2022 24% $1.80 $1,000,000 $(267,000) $733,000 At December 31, 2020 7/31/2022 24% $1.80 $1,000,000 $(507,000) $493,000 The Company recorded amortization expense for the debt discount on the July 2019 three nine September 30, 2021 three nine September 30, 2020. July 2019 three nine September 30, 2021 2020. |
Note 7 - Leases
Note 7 - Leases | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 7. LEASES The Company leases an approximately 28,000 first 2019 May 2024. Operating Leases Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not not The following summarizes the Company’s operating leases: September 30, 2021 December 31, 2020 Right-of-use operating lease assets, net $ 614,000 $ 730,000 Current lease liability (included in other current liabilities) 193,000 157,000 Non-current lease liability 455,000 604,000 Weighted average remaining lease term 2.7 3.4 Discount rate 22 % 22 % Maturities of lease liabilities by year for our operating leases are as follows: 2021 (Remaining) $ 78,000 2022 319,000 2023 328,000 2024 139,000 Total lease payments $ 864,000 Less: imputed interest (217,000 ) Present value of operating lease liabilities $ 647,000 Statement of Cash Flows In January 2019, three nine September 30, 2021 three nine September 30, 2020, Operating Lease Costs Operating lease costs were $107,000 and $316,000 for the three nine September 30, 2021 three nine September 30, 2020, Finance Leases Finance leases are included in equipment and other current and non-current liabilities on the condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively on the statement of operations. These leases were not three nine September 30, 2021 2020. |
Note 8 - Commitments and Contin
Note 8 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 8. COMMITMENTS AND CONTINGENCIES Contingencies In the normal course of operations, the Company may September 30, 2021, may not Financial Covenants On July 13, 2020, #2 July 13, 2020 ( May 15, 2017 #1 March 16, 2020 one September 30, 2021. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the nine September 30, 2021 Balance at December 31, 2020 $ 154,000 Warranties issued during the period 53,000 Settlements made during the period (140,000 ) Changes in liability for pre-existing warranties during the period -- Balance at September 30, 2021 $ 67,000 |
Note 9 - Paycheck Protection Pr
Note 9 - Paycheck Protection Program | 9 Months Ended |
Sep. 30, 2021 | |
Paycheck Protection Program CARES Act [Member] | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | 9. PAYCHECK PROTECTION PROGRAM On April 21, 2020, two 1.00% first six may may December 2020, March 30, 2021 nine September 30, 2021, |
Note 10 - Employee Retention Ta
Note 10 - Employee Retention Tax Credit | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Retirement Benefits [Text Block] | 10. EMPLOYEE RETENTION TAX CREDIT Employee Retention Tax Credits (“ERTC”), created in the March 2020 2021 2021, 19 70% January 1, 2021 December 31, 2021. $10,000 2021 $7,000 The Company is eligible to receive the ERTC credits under the gross receipts decline test when comparing the first, second third 2021 2019, first three 2021 first three 2021, three nine September 30, 2021, September 30, 2021. |
Note 11 - Stockholders' Equity
Note 11 - Stockholders' Equity | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 11. STOCKHOLDERS ’ EQUITY Common Stock On December 13, 2019, may May 19, 2020 September 30, 2021, nine September 30, 2021, Stock Based Compensation In May 2021, five June 2020. No three June 30, 2021. The Company recorded stock-based compensation of $92,000 and $2,449,000 for the three nine September 30, 2021, three nine September 30, 2020, Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenues $ 4,000 $ 3,000 $ 14,000 $ 5,000 Selling, general and administrative 64,000 195,000 2,194,000 538,000 Research and development 24,000 36,000 241,000 72,000 $ 92,000 $ 234,000 $ 2,449,000 $ 615,000 The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2020 889,636 $ 8.57 8.7 $ -- Cancelled / Forfeited 523,041 Outstanding at September 30, 2021 366,595 $ 11.86 7.1 $ -- Vested and expected to vest at September 30, 2021 331,128 $ 12.36 6.9 $ -- Exercisable at September 30, 2021 244,245 $ 13.97 7.0 $ -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no options exercised during the nine September 30, 2021. Warrants A summary of warrant activity for the nine September 30, 2021 Number of Shares Weighted-Average Exercise Price Per Share Weighted- Average Remaining Contract Term Balance at December 31, 2020 1,116,484 $ 37.27 0.49 Warrants expired 463,236 Warrants exercised -- $ -- Outstanding at September 30, 2021 653,248 $ 6.97 1.70 Exercisable at September 30, 2021 653,248 $ 6.97 1.70 |
Note 12 - Major Customers and A
Note 12 - Major Customers and Accounts Receivable | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | 12. MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE The Company had certain customers whose revenue individually represented 10% 10% For net revenues, one second third three September 30, 2021 2020, nine September 30, 2021 2020, one second third At September 30, 2021, December 31, 2020, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Standards In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020. not nine September 30, 2021 not In January 2020, 2020 01, Investments Equity Securities (Topic 321 Equity Method and Joint Ventures (Topic 323 815 321, 323, 815 December 15, 2020, not |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition Revenue is recognized based on the five 606. The following tables summarize the revenues by product line: Three Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,217,000 $ 72,000 $ 21,000 $ 2,310,000 BioArchive 221,000 297,000 -- 518,000 CAR-TXpress 160,000 31,000 71,000 262,000 Manual Disposables 55,000 -- -- 55,000 Other 9,000 -- 4,000 13,000 Total $ 2,662,000 $ 400,000 $ 96,000 $ 3,158,000 Nine Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 3,490,000 $ 159,000 $ 1,000 $ 3,670,000 BioArchive 652,000 1,165,000 -- 1,817,000 CAR-TXpress 702,000 89,000 214,000 1,005,000 Manual Disposables 300,000 -- -- 300,000 Other 46,000 -- 38,000 84,000 Total $ 5,190,000 $ 1,413,000 $ 273,000 $ 6,876,000 Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three nine September 30, 2021 nine September 30, 2021, Exclusivity Fee On August 30, 2019, five two two four X three nine September 30, 2021 2020, Distribution Agreement The Company signed a new agreement with its AXP distributor in China through 2023. 2021, two 2024. September 30, 2021, five per quarter September 30, 2021, Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2021 2022 2023 2024 2025 and beyond Total Service revenue $ 359,000 $ 962,000 $ 462,000 $ 189,000 $ 85,000 $ 2,057,000 Clinical revenue 3,000 13,000 13,000 13,000 160,000 202,000 Device revenue (1) 21,000 674,000 674,000 41,000 -- 1,410,000 Exclusivity fee 72,000 286,000 286,000 286,000 476,000 1,406,000 Total $ 455,000 $ 1,935,000 $ 1,435,000 $ 529,000 $ 721,000 $ 5,075,000 ( 1 Represents the minimum purchase requirements related to the Company AXP distributor in China Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not three nine September 30, 2021, one |
Note 3 - Summary of Significa_2
Note 3 - Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | Three Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,217,000 $ 72,000 $ 21,000 $ 2,310,000 BioArchive 221,000 297,000 -- 518,000 CAR-TXpress 160,000 31,000 71,000 262,000 Manual Disposables 55,000 -- -- 55,000 Other 9,000 -- 4,000 13,000 Total $ 2,662,000 $ 400,000 $ 96,000 $ 3,158,000 Nine Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 3,490,000 $ 159,000 $ 1,000 $ 3,670,000 BioArchive 652,000 1,165,000 -- 1,817,000 CAR-TXpress 702,000 89,000 214,000 1,005,000 Manual Disposables 300,000 -- -- 300,000 Other 46,000 -- 38,000 84,000 Total $ 5,190,000 $ 1,413,000 $ 273,000 $ 6,876,000 Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] | Remainder of 2021 2022 2023 2024 2025 and beyond Total Service revenue $ 359,000 $ 962,000 $ 462,000 $ 189,000 $ 85,000 $ 2,057,000 Clinical revenue 3,000 13,000 13,000 13,000 160,000 202,000 Device revenue (1) 21,000 674,000 674,000 41,000 -- 1,410,000 Exclusivity fee 72,000 286,000 286,000 286,000 476,000 1,406,000 Total $ 455,000 $ 1,935,000 $ 1,435,000 $ 529,000 $ 721,000 $ 5,075,000 |
Note 4 - Net Loss Per Share (Ta
Note 4 - Net Loss Per Share (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | 2021 2020 Common stock equivalents of convertible promissory notes and accrued interest 7,071,241 6,988,334 Vested Series A warrants -- 40,441 Unvested Series A warrants (1) -- 69,853 Warrants – other 653,248 1,006,190 Stock options 366,595 892,149 Total 8,091,084 8,996,967 |
Note 5 - Related Party Transa_2
Note 5 - Related Party Transactions (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Related Party Transactions [Table Text Block] | Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At September 30, 2021 3/6/2022 22% $1.80 $10,000,000 $(1,583,000) $8,417,000 At December 31, 2020 3/6/2022 22% $1.80 $10,000,000 $(4,065,000) $5,935,000 |
Note 6 - Convertible Promisso_2
Note 6 - Convertible Promissory Note (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Convertible Debt [Table Text Block] | Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At September 30, 2021 7/31/2022 24% $1.80 $1,000,000 $(267,000) $733,000 At December 31, 2020 7/31/2022 24% $1.80 $1,000,000 $(507,000) $493,000 |
Note 7 - Leases (Tables)
Note 7 - Leases (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Lease, Cost [Table Text Block] | September 30, 2021 December 31, 2020 Right-of-use operating lease assets, net $ 614,000 $ 730,000 Current lease liability (included in other current liabilities) 193,000 157,000 Non-current lease liability 455,000 604,000 Weighted average remaining lease term 2.7 3.4 Discount rate 22 % 22 % |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | 2021 (Remaining) $ 78,000 2022 319,000 2023 328,000 2024 139,000 Total lease payments $ 864,000 Less: imputed interest (217,000 ) Present value of operating lease liabilities $ 647,000 |
Note 8 - Commitments and Cont_2
Note 8 - Commitments and Contingencies (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Product Warranty Liability [Table Text Block] | Balance at December 31, 2020 $ 154,000 Warranties issued during the period 53,000 Settlements made during the period (140,000 ) Changes in liability for pre-existing warranties during the period -- Balance at September 30, 2021 $ 67,000 |
Note 11 - Stockholders' Equity
Note 11 - Stockholders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenues $ 4,000 $ 3,000 $ 14,000 $ 5,000 Selling, general and administrative 64,000 195,000 2,194,000 538,000 Research and development 24,000 36,000 241,000 72,000 $ 92,000 $ 234,000 $ 2,449,000 $ 615,000 |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2020 889,636 $ 8.57 8.7 $ -- Cancelled / Forfeited 523,041 Outstanding at September 30, 2021 366,595 $ 11.86 7.1 $ -- Vested and expected to vest at September 30, 2021 331,128 $ 12.36 6.9 $ -- Exercisable at September 30, 2021 244,245 $ 13.97 7.0 $ -- |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of Shares Weighted-Average Exercise Price Per Share Weighted- Average Remaining Contract Term Balance at December 31, 2020 1,116,484 $ 37.27 0.49 Warrants expired 463,236 Warrants exercised -- $ -- Outstanding at September 30, 2021 653,248 $ 6.97 1.70 Exercisable at September 30, 2021 653,248 $ 6.97 1.70 |
Note 1 - Description of Busin_2
Note 1 - Description of Business and Basis of Presentation (Details Textual) - CAR-TXpress [Member] | Sep. 30, 2021 |
Noncontrolling Interest, Ownership Percentage by Parent | 80.00% |
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 20.00% |
Note 2 - Going Concern (Details
Note 2 - Going Concern (Details Textual) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Cash and Cash Equivalents, at Carrying Value, Ending Balance | $ 7,634,000 | $ 7,161,000 |
Working Capital | $ 2,146,000 |
Note 3 - Summary of Significa_3
Note 3 - Summary of Significant Accounting Policies (Details Textual) | Aug. 30, 2019USD ($) | Sep. 30, 2021USD ($) | Sep. 30, 2021USD ($) | Dec. 31, 2020USD ($) |
Contract with Customer, Liability, Revenue Recognized | $ 118,000 | $ 521,000 | ||
Contract with Customer, Liability, Current | 943,000 | 943,000 | $ 608,000 | |
Contract with Customer, Liability, Noncurrent | 1,395,000 | 1,395,000 | $ 1,596,000 | |
Exclusivity Fee [Member] | ||||
Contract with Customer, Liability, Revenue Recognized | 71,000 | 214,000 | ||
Contract with Customer, Liability, Current | 286,000 | 286,000 | ||
Contract with Customer, Liability, Noncurrent | 1,119,000 | 1,119,000 | ||
Contract with Customer, Liability, Total | $ 2,000,000 | 1,405,000 | 1,405,000 | |
Proceeds from Customers | $ 2,000,000 | |||
Supply Agreement [Member] | ||||
Supply Agreement, Term (Year) | 5 years | |||
Supply Agreement, Renewal Term, Number of Options | 2 | |||
Supply Agreement, Renewal Term, Per Option (Year) | 2 years | |||
Supply Agreement [Member] | Maximum [Member] | ||||
Supply Agreement, Renewal Term (Year) | 4 years | |||
Distribution Agreement with AXP Distributor in China [Member] | ||||
Contract with Customer, Liability, Current | 82,000 | 82,000 | ||
Contract with Customer, Liability, Noncurrent | 27,000 | 27,000 | ||
Distributor Agreement, Minimum Purchase, Current Fiscal Year | 1,400,000 | |||
Distributor Agreement, Purchase, Each year, Next Two Years | 650,000 | |||
Lessor, Sales-type Lease, Assumptions and Judgments, Value of Underlying Asset, Amount | $ 180,000 | $ 180,000 | ||
Property, Plant and Equipment, Useful Life (Year) | 5 years | |||
Distribution Agreement with AXP Distributor in China [Member] | Device Revenue [Member] | ||||
Expected Lease Revenue Per Quarter | $ 21,000 |
Note 3 - Summary of Significa_4
Note 3 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Net revenues | $ 3,158,000 | $ 2,355,000 | $ 6,876,000 | $ 7,797,000 |
Device [Member] | AXP [Member] | ||||
Net revenues | 2,310,000 | 1,169,000 | 3,670,000 | 4,112,000 |
Device [Member] | BioArchive [Member] | ||||
Net revenues | 518,000 | 619,000 | 1,817,000 | 1,575,000 |
Device [Member] | CAR-TXpress [Member] | ||||
Net revenues | 262,000 | 425,000 | 1,005,000 | 1,296,000 |
Device [Member] | Manual Disposables [Member] | ||||
Net revenues | 55,000 | 100,000 | 300,000 | 499,000 |
Device [Member] | Other Subsegments [Member] | ||||
Net revenues | 13,000 | 42,000 | 84,000 | 315,000 |
Device Revenue [Member] | ||||
Net revenues | 2,662,000 | 1,932,000 | 5,190,000 | 6,494,000 |
Device Revenue [Member] | Device [Member] | AXP [Member] | ||||
Net revenues | 2,217,000 | 1,137,000 | 3,490,000 | 4,009,000 |
Device Revenue [Member] | Device [Member] | BioArchive [Member] | ||||
Net revenues | 221,000 | 337,000 | 652,000 | 675,000 |
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member] | ||||
Net revenues | 160,000 | 332,000 | 702,000 | 1,035,000 |
Device Revenue [Member] | Device [Member] | Manual Disposables [Member] | ||||
Net revenues | 55,000 | 100,000 | 300,000 | 499,000 |
Device Revenue [Member] | Device [Member] | Other Subsegments [Member] | ||||
Net revenues | 9,000 | 26,000 | 46,000 | 276,000 |
Service [Member] | ||||
Net revenues | 400,000 | 336,000 | 1,413,000 | 1,050,000 |
Service [Member] | Device [Member] | AXP [Member] | ||||
Net revenues | 72,000 | 32,000 | 159,000 | 103,000 |
Service [Member] | Device [Member] | BioArchive [Member] | ||||
Net revenues | 297,000 | 282,000 | 1,165,000 | 900,000 |
Service [Member] | Device [Member] | CAR-TXpress [Member] | ||||
Net revenues | 31,000 | 22,000 | 89,000 | 47,000 |
Other [Member] | ||||
Net revenues | 96,000 | 87,000 | 273,000 | 253,000 |
Other [Member] | Device [Member] | CAR-TXpress [Member] | ||||
Net revenues | 71,000 | 71,000 | 214,000 | 214,000 |
Other [Member] | Device [Member] | Other Subsegments [Member] | ||||
Net revenues | $ 4,000 | $ 16,000 | $ 38,000 | $ 39,000 |
Note 3 - Summary of Significa_5
Note 3 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details) | Sep. 30, 2021USD ($) | |
Revenue, Remaining Performance Obligation, Amount | $ 5,075,000 | |
Service [Member] | ||
Revenue, Remaining Performance Obligation, Amount | 2,057,000 | |
Clinical Revenue [Member] | ||
Revenue, Remaining Performance Obligation, Amount | 202,000 | |
Device Revenue [Member] | ||
Revenue, Remaining Performance Obligation, Amount | 1,410,000 | [1] |
Exclusivity Fee [Member] | ||
Revenue, Remaining Performance Obligation, Amount | $ 1,406,000 | |
[1] | Represents the minimum purchase requirements related to the Company AXP distributor in China |
Note 3 - Summary of Significa_6
Note 3 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details) | Sep. 30, 2021USD ($) | |
Revenue, Remaining Performance Obligation, Amount | $ 5,075,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 6 months | |
Revenue, Remaining Performance Obligation, Amount | $ 455,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 1,935,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 1,435,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 529,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 721,000 | |
Service [Member] | ||
Revenue, Remaining Performance Obligation, Amount | $ 2,057,000 | |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 3 months | |
Revenue, Remaining Performance Obligation, Amount | $ 359,000 | |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 962,000 | |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 462,000 | |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 189,000 | |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 85,000 | |
Clinical Revenue [Member] | ||
Revenue, Remaining Performance Obligation, Amount | $ 202,000 | |
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 3 months | |
Revenue, Remaining Performance Obligation, Amount | $ 3,000 | |
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 13,000 | |
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 13,000 | |
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 13,000 | |
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 160,000 | |
Device Revenue [Member] | ||
Revenue, Remaining Performance Obligation, Amount | $ 1,410,000 | [1] |
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 3 months | [1] |
Revenue, Remaining Performance Obligation, Amount | $ 21,000 | [1] |
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | [1] |
Revenue, Remaining Performance Obligation, Amount | $ 674,000 | [1] |
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | [1] |
Revenue, Remaining Performance Obligation, Amount | $ 674,000 | [1] |
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | [1] |
Revenue, Remaining Performance Obligation, Amount | $ 41,000 | [1] |
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | [1] |
Exclusivity Fee [Member] | ||
Revenue, Remaining Performance Obligation, Amount | $ 1,406,000 | |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 3 months | |
Revenue, Remaining Performance Obligation, Amount | $ 72,000 | |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 286,000 | |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 286,000 | |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 286,000 | |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Amount | $ 476,000 | |
[1] | Represents the minimum purchase requirements related to the Company AXP distributor in China |
Note 4 - Net Loss Per Share - A
Note 4 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | ||
Anti-dilutive securities (in shares) | 8,091,084 | 8,996,967 | |
Convertible Debt Securities [Member] | |||
Anti-dilutive securities (in shares) | 7,071,241 | 6,988,334 | |
Vested Series A Warrants [Member] | |||
Anti-dilutive securities (in shares) | 40,441 | ||
Unvested Series A Warrants [Member] | |||
Anti-dilutive securities (in shares) | [1] | 69,853 | |
Warrant, Other [Member] | |||
Anti-dilutive securities (in shares) | 653,248 | 1,006,190 | |
Share-based Payment Arrangement, Option [Member] | |||
Anti-dilutive securities (in shares) | 366,595 | 892,149 | |
[1] | The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants remained outstanding but unvested until they expired in February 2021. |
Note 5 - Related Party Transa_3
Note 5 - Related Party Transactions (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||||||||
Mar. 31, 2021 | Jan. 31, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | Apr. 28, 2020 | Nov. 26, 2019 | Dec. 31, 2018 | Apr. 16, 2018 | Mar. 31, 2017 | |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total | $ (1,792,000) | $ (2,609,000) | $ (8,994,000) | $ (13,862,000) | ||||||||
Assets, Current, Total | 16,881,000 | 16,881,000 | $ 15,298,000 | |||||||||
Liabilities, Current, Total | $ 14,735,000 | 14,735,000 | $ 6,143,000 | |||||||||
Interest Paid, Excluding Capitalized Interest, Operating Activities | 2,262,000 | 2,094,000 | ||||||||||
Amortization of Debt Discount (Premium) | $ 2,723,000 | 2,165,000 | ||||||||||
Boyalife Asset Holding II [Member] | Convertible Debt [Member] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 22.00% | 22.00% | 22.00% | |||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 1.80 | $ 1.80 | $ 1.80 | $ 1.80 | $ 16.10 | |||||||
Boyalife Asset Holding II [Member] | Revolving Credit Facility [Member] | ||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 10,000,000 | |||||||||||
Long-term Line of Credit, Total | $ 10,000,000 | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 22.00% | |||||||||||
Interest Paid, Excluding Capitalized Interest, Operating Activities | $ 2,082,000 | |||||||||||
Amortization of Debt Discount (Premium) | $ 827,000 | 827,000 | $ 2,482,000 | 2,103,000 | ||||||||
Interest Expense, Debt, Excluding Amortization | 562,000 | $ 562,000 | 1,668,000 | $ 1,519,000 | ||||||||
Interest Payable | $ 1,668,000 | $ 1,668,000 | $ 2,082,000 | |||||||||
ImmuneCyte and Shangai KDWinfo Technology Co. Ltd. [Member] | Boyalife’s Cellular Therapy Division [Member] | ||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 12,000,000 | |||||||||||
ImmuneCyte [Member] | Boyalife’s Cellular Therapy Division [Member] | ||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | 500,000 | |||||||||||
ImmuneCyte [Member] | ||||||||||||
Equity Method Investment, Ownership Percentage | 8.64% | 18.79% | 8.64% | 18.79% | 20.00% | |||||||
Dilution Gain from Equity Method Investments | $ 262,000 | |||||||||||
Equity Method Investment Accumulated Gain Loss | (428,000) | |||||||||||
Income (Loss) from Equity Method Investments, Total | 0 | |||||||||||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total | 750,000 | |||||||||||
Assets, Current, Total | $ 3,283,000 | 3,283,000 | ||||||||||
Liabilities, Current, Total | $ 2,970,000 | $ 2,970,000 | ||||||||||
ImmuneCyte [Member] | HealthBanks Biotech [Member] | ||||||||||||
Equity Method Investment, Ownership Percentage | 75.16% | 75.16% | 80.00% | |||||||||
ImmuneCyte [Member] | Private Institution [Member] | ||||||||||||
Equity Method Investment, Ownership Percentage | 6.05% | 6.05% |
Note 5 - Related Party Transa_4
Note 5 - Related Party Transactions - Summarizes the Note (Details) - Boyalife Asset Holding II [Member] - Convertible Debt [Member] - USD ($) | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2018 | Apr. 16, 2018 | |
Debt Instrument, Maturity Date | Mar. 6, 2022 | Mar. 6, 2022 | ||
State interest rate | 22.00% | 22.00% | ||
Conversion price (in dollars per share) | $ 1.80 | $ 1.80 | $ 1.80 | $ 16.10 |
Face value | $ 10,000,000 | $ 10,000,000 | ||
Remaining debt discount | (1,583,000) | (4,065,000) | ||
Carrying Value | $ 8,417,000 | $ 5,935,000 |
Note 6 - Convertible Promisso_3
Note 6 - Convertible Promissory Note (Details Textual) - USD ($) | Jul. 23, 2019 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 |
Amortization of Debt Discount (Premium) | $ 2,723,000 | $ 2,165,000 | ||||
Convertible Debt [Member] | The July 2019 Note [Member] | ||||||
Debt Instrument, Face Amount | $ 1,000,000 | $ 1,000,000 | $ 1,000,000 | $ 1,000,000 | ||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 1.80 | $ 1.80 | $ 1.80 | |||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 90.00% | |||||
Debt Instrument, Interest Rate, Stated Percentage | 24.00% | 24.00% | 24.00% | 24.00% | ||
Amortization of Debt Discount (Premium) | $ 80,000 | $ 27,000 | $ 241,000 | 107,000 | ||
Interest Expense, Debt, Total | $ 60,000 | $ 60,000 | $ 180,000 | $ 180,000 | ||
Convertible Debt [Member] | The July 2019 Note [Member] | Maximum [Member] | ||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 1.80 | |||||
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member] | ||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.50 |
Note 6 - Convertible Promisso_4
Note 6 - Convertible Promissory Note - Convertible Promissory Note (Details) - Convertible Debt [Member] - The July 2019 Note [Member] - USD ($) | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2021 | Dec. 31, 2020 | Jul. 23, 2019 | |
Maturity Date | Jul. 31, 2022 | Jul. 31, 2022 | |
Stated Interest Rate | 24.00% | 24.00% | 24.00% |
Conversion Price (in dollars per share) | $ 1.80 | $ 1.80 | |
Face Value | $ 1,000,000 | $ 1,000,000 | $ 1,000,000 |
Remaining debt discount | (267,000) | (507,000) | |
Carrying Value | $ 733,000 | $ 493,000 |
Note 7 - Leases (Details Textua
Note 7 - Leases (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | Jan. 01, 2019 | |
Operating Lease, Right-of-Use Asset | $ 614,000 | $ 614,000 | $ 730,000 | |||
Operating Lease, Payments | 78,000 | $ 76,000 | 231,000 | $ 225,000 | ||
Operating Lease, Cost | $ 107,000 | $ 135,000 | $ 316,000 | $ 343,000 | ||
Accounting Standards Update 2016-02 [Member] | ||||||
Operating Lease, Right-of-Use Asset | $ 966,000 |
Note 7 - Leases - Lease Informa
Note 7 - Leases - Lease Information (Details) - USD ($) | Sep. 30, 2021 | Dec. 31, 2020 |
Right-of-use operating lease assets, net | $ 614,000 | $ 730,000 |
Non-current lease liability | $ 455,000 | $ 604,000 |
Weighted average remaining lease term (Year) | 2 years 8 months 12 days | 3 years 4 months 24 days |
Discount rate | 22.00% | 22.00% |
Current Liabilities [Member] | ||
Current lease liability (included in other current liabilities) | $ 193,000 | $ 157,000 |
Note 7 - Leases - Maturities of
Note 7 - Leases - Maturities of Lease Liabilities (Details) | Sep. 30, 2021USD ($) |
2021 (Remaining) | $ 78,000 |
2022 | 319,000 |
2023 | 328,000 |
2024 | 139,000 |
Total lease payments | 864,000 |
Less: imputed interest | (217,000) |
Present value of operating lease liabilities | $ 647,000 |
Note 8 - Commitments and Cont_3
Note 8 - Commitments and Contingencies (Details Textual) - USD ($) | 9 Months Ended | |
Sep. 30, 2021 | Jul. 13, 2020 | |
Short Term Investment Minimum | $ 1,000,000 | |
Minimum [Member] | ||
Period Of Warranty On Products (Year) | 1 year | |
Maximum [Member] | ||
Period Of Warranty On Products (Year) | 2 years |
Note 8 - Commitments and Cont_4
Note 8 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details) | 9 Months Ended |
Sep. 30, 2021USD ($) | |
Balance | $ 154,000 |
Warranties issued during the period | 53,000 |
Settlements made during the period | (140,000) |
Balance | $ 67,000 |
Note 9 - Paycheck Protection _2
Note 9 - Paycheck Protection Program (Details Textual) - USD ($) | Apr. 21, 2020 | Sep. 30, 2021 |
Gain (Loss) on Extinguishment of Debt, Total | $ 652,000 | |
Paycheck Protection Program CARES Act [Member] | ||
Proceeds from Issuance of Long-term Debt, Total | $ 646,000 | |
Gain (Loss) on Extinguishment of Debt, Total | $ 652,000 |
Note 10 - Employee Retention _2
Note 10 - Employee Retention Tax Credit (Details Textual) | 9 Months Ended |
Sep. 30, 2021USD ($) | |
Employee Retention Tax Credit | $ 842,000 |
Note 11 - Stockholders' Equit_2
Note 11 - Stockholders' Equity (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 22 Months Ended | |||||
May 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | May 19, 2020 | Dec. 13, 2019 | |
Proceeds from Issuance of Common Stock, Net | $ 6,832,000 | $ 5,580,000 | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares) | 523,041 | ||||||||
Share-based Payment Arrangement, Expense | $ 92,000 | $ 234,000 | $ 2,449,000 | $ 615,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 0 | ||||||||
Executive Officer [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares) | 490,000 | ||||||||
Executive Officer [Member] | Share-based Payment Arrangement, Option [Member] | |||||||||
Share-based Payment Arrangement, Accelerated Cost | $ 2,008,000 | ||||||||
At The Market Offering Agreement [Member] | |||||||||
Maximum Offering Price for Issuance of Common Stock | $ 15,280,313 | $ 4,400,000 | |||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,976,832 | 5,597,484 | |||||||
Proceeds from Issuance of Common Stock | $ 15,280,000 | ||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 2.73 | $ 2.73 | $ 2.73 | ||||||
Proceeds from Issuance of Common Stock, Net | $ 6,832,000 | $ 14,568,000 | |||||||
Payments of Stock Issuance Costs | $ 224,000 | $ 712,000 |
Note 11 - Stockholders' Equit_3
Note 11 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Stock-based compensation | $ 92,000 | $ 234,000 | $ 2,449,000 | $ 615,000 |
Cost of Sales [Member] | ||||
Stock-based compensation | 4,000 | 3,000 | 14,000 | 5,000 |
Selling, General and Administrative Expenses [Member] | ||||
Stock-based compensation | 64,000 | 195,000 | 2,194,000 | 538,000 |
Research and Development Expense [Member] | ||||
Stock-based compensation | $ 24,000 | $ 36,000 | $ 241,000 | $ 72,000 |
Note 11 - Stockholders' Equit_4
Note 11 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) | 9 Months Ended |
Sep. 30, 2021$ / sharesshares | |
Outstanding, options (in shares) | 889,636 |
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares | $ 8.57 |
Cancelled / Forfeited, options (in shares) | 523,041 |
Outstanding, options (in shares) | 366,595 |
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares | $ 11.86 |
Outstanding, weighted average remaining contractual life, options (Year) | 7 years 1 month 6 days |
Vested and expected to vest, options (in shares) | 331,128 |
Vested and expected to vest, weighted average exercise price, options (in dollars per share) | $ / shares | $ 12.36 |
Vested and expected to vest, weighted average remaining contractual life, options (Year) | 6 years 10 months 24 days |
Exercisable, options (in shares) | 244,245 |
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares | $ 13.97 |
Exercisable, weighted average remaining contractual life, options (Year) | 7 years |
Note 11 - Stockholders' Equit_5
Note 11 - Stockholders' Equity - Warrant Activity (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2021 | Dec. 31, 2020 | |
Outstanding (in shares) | 1,116,484 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 37.27 | |
Outstanding, Weighted Average Remaining Contract Term (Year) | 1 year 8 months 12 days | 5 months 26 days |
Warrants expired (in shares) | 463,236 | |
Outstanding (in shares) | 653,248 | 1,116,484 |
Outstanding, weighted average exercise price (in dollars per share) | $ 6.97 | $ 37.27 |
Exercisable (in shares) | 653,248 | |
Exercisable, weighted average exercise price (in dollars per share) | $ 6.97 | |
Exercisable, Weighted Average Remaining Contract Term (Year) | 1 year 8 months 12 days |
Note 12 - Major Customers and_2
Note 12 - Major Customers and Accounts Receivable (Details Textual) - Customer Concentration Risk [Member] | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | |
Revenue Benchmark [Member] | Customer 1 [Member] | |||||
Concentration Risk, Percentage | 42.00% | 20.00% | 19.00% | 12.00% | |
Revenue Benchmark [Member] | Customer 2 [Member] | |||||
Concentration Risk, Percentage | 24.00% | 22.00% | 17.00% | 27.00% | |
Revenue Benchmark [Member] | Customer 3 [Member] | |||||
Concentration Risk, Percentage | 0.00% | 10.00% | 10.00% | 12.00% | |
Accounts Receivable [Member] | |||||
Number of Major Customers | 2 | 3 | |||
Accounts Receivable [Member] | Two Customers [Member] | |||||
Concentration Risk, Percentage | 67.00% | ||||
Accounts Receivable [Member] | Three Customers [Member] | |||||
Concentration Risk, Percentage | 72.00% |